Hepatitis C Virus (HCV) Genotype with Reflex to HCV NS5A Drug Resistance by Sequencing
Order before initiating treatment with NS5A inhibitors. Use to determine HCV type 1-6 after molecular confirmation of positive HCV screen. If genotype “1a or 1b” is determined, testing will reflex to HCV NS5A for genotype differentiation and drug resistance by sequencing.
Polymerase Chain Reaction/Sequencing
Lavender (EDTA), Pink (K2EDTA), Plasma Preparation Tube (PPT), or Serum Separator Tube (SST).
Separate from cells ASAP or within 2 hours of collection. Transfer 2 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 1.5 mL)
Ambient: Unacceptable; Refrigerated: 72 hours; Frozen: 4 months
Refer to report.
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
This test may be unsuccessful if the HCV RNA viral load is less than log 3.6 or 4000 IU/mL. If initial result is Type "1a or 1b", then HCV NS5A Drug Resistance by Sequencing will be added. Additional charges apply.
87902; if reflexed, add 87902
|Component Test Code*||Component Chart Name||LOINC|
|0055593||HCV Genotype by Sequencing||32286-7|